Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elshad Hasanov MD, PhD

Elshad Hasanov MD, PhD

Medical Oncology Fellow, University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. Hasanov is a medical oncology fellow at the University of Texas MD Anderson Cancer Center. His clinical and research interests span various approaches focusing on understanding the biology of kidney cancer and developing better treatments for the patients. He was born and raised in Azerbaijan. He received MD and PhD in Tumor Biology and Immunology from the Hacettepe University Faculty of Medicine in Turkey. During his PhD training he worked in Dr. Cheryl Walker’s laboratory at Texas A&M Institute of Biosciences and Technology and revealed a new signaling pathway downstream of von Hippel-Linadu (VHL) tumor suppressor in kidney cancer. He showed that VHL, which is an E3-ligase, target Aurora Kinase A for protesomal degradation by ubiquitination. The downregulation of AURKA by VHL, plays a critical role in primary cilia maintenance and kidney cancer, offering new therapeutic opportunities for this disease. He subsequently completed the Internal Medicine Residency training at the University of Texas Houston McGovern Medical School.

His current research focuses on understanding the unique clinical and biological features of brain metastasis in renal cell carcinoma patients; also exploring the mechanisms behind the immune checkpoint resistance and immune checkpoint related toxicity. Dr. Hasanov is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO). He has published several peer-reviewed original papers, case reports, and reviews in leading journals including Journal of Clinical Oncology, Oncogene, Annals of Oncology, the Lancet.

Disclosures

No disclosures reported.

Recent Contributions to PracticeUpdate:

  1. FDA Approval for Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
  2. Frontline Management of Renal Cell Carcinoma
  3. ASCO: Updated Results of a Clinical Trial Evaluating Pembrolizumab Plus Axitinib for Frontline Treatment of Advanced RCC
  4. ASCO: Savolitinib for Patients With MET-Driven Papillary Renal Cell Carcinoma
  5. ASCO: A Novel Therapy for VHL Disease-Associated Renal Cell Carcinoma
  6. Contextualizing New Data on Checkpoint Inhibitors for Non–Clear Cell RCC
  7. AACR: Early Data on Targeting PBRM1 Mutations
  8. AACR: Clinical Implications of Mutational Data From Brain Metastases
  9. FDA Approved Tucatinib for HER2-Positive Breast Cancer
  10. FDA-Approved Nivolumab and Ipilimumab for HCC

Recently Updated